5-甲基-1-苯基-1H-吡唑-4-甲酸乙酯 | 89193-16-8

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-甲基-1-苯基-1H-吡唑-4-甲酸乙酯
• 中文别名: 1-苯基-5-甲基-1H-吡唑-4-羧酸乙酯
• 英文名称: ethyl 5-methyl-1-phenyl-1H-pyrazole-4-carboxylate
• 英文别名: ethyl 5-methyl-1-phenyl-1H-4-pyrazolecarboxylate；ethyl 5-methyl-1-phenylpyrazole-4-carboxylate
• CAS: 89193-16-8
• 化学式: C₁₃H₁₄N₂O₂
• mdl: MFCD00020741
• 分子量: 230.266
• InChiKey: XYIOIOHRWLZCDM-UHFFFAOYSA-N

物化性质

• 熔点：
  47-49°C
• 密度：
  1.13
• 溶解度：
  可溶于二氯甲烷、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933199090
• 储存条件：
  存储条件：2-8°C，密封于干燥处。

SDS

Name:	Ethyl 5-methyl-1-phenyl-1H-pyrazole-4-carboxylate 97% Material Safety Data Sheet
Synonym:
CAS:	89193-16-8

Section 1 - Chemical Product MSDS Name:Ethyl 5-methyl-1-phenyl-1H-pyrazole-4-carboxylate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
89193-16-8	Ethyl 5-methyl-1-phenyl-1H-pyrazole-4-	97%	289-479-7

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 89193-16-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 51 - 52 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C13H14N2O2
Molecular Weight: 230

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, bases.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 89193-16-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 5-methyl-1-phenyl-1H-pyrazole-4-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 89193-16-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 89193-16-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 89193-16-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-甲基-1-苯基-1H-吡唑-4-甲酸乙酯 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 5.0h， 以92%的产率得到5-甲基-1-苯基-1H-吡唑-4-羧酸
  参考文献：
  名称：

  2-二甲基氨基亚甲基-1,3-二酮与二亲核试剂的反应。六。1,5-二取代的1 H-吡唑-4-羧酸乙酯或甲酯的合成

  摘要：

  3-氧代链烷酸乙酯或甲基酯与N，N-二甲基甲酰胺二甲基乙缩醛的反应通常以优异的产率得到一系列乙基或甲基2-二甲氨基亚甲基-3-氧代链烷酸酯II，其与苯肼反应得到5-取代的1的酯。 -苯基-1 H-吡唑-4-羧酸III高收率。将酯III水解成相对的5-取代的1-苯基-1 H-吡唑-4-羧酸，将其通过加热转化成5-取代的1-苯基-1 H-吡唑以优异的产率转化。的反应II与甲基肼在3-和一般的混合物，得到5-取代的乙基1-甲基-1- ħ-吡唑-4-羧酸酯，除IIg以外，产生高产率的5-苄基-1-甲基-1 H-吡唑-4-羧酸甲酯，将其水解为相对的吡唑羧酸。通过以定量收率加热5-苄基-1-甲基-1 H-吡唑来提供。

  DOI：

  10.1002/jhet.5570240634
• 作为产物：
  描述：

  乙酰乙酸乙酯 以 乙醇 为溶剂， 反应 3.0h， 生成 5-甲基-1-苯基-1H-吡唑-4-甲酸乙酯
  参考文献：
  名称：

  2-二甲基氨基亚甲基-1,3-二酮与二亲核试剂的反应。六。1,5-二取代的1 H-吡唑-4-羧酸乙酯或甲酯的合成

  摘要：

  3-氧代链烷酸乙酯或甲基酯与N，N-二甲基甲酰胺二甲基乙缩醛的反应通常以优异的产率得到一系列乙基或甲基2-二甲氨基亚甲基-3-氧代链烷酸酯II，其与苯肼反应得到5-取代的1的酯。 -苯基-1 H-吡唑-4-羧酸III高收率。将酯III水解成相对的5-取代的1-苯基-1 H-吡唑-4-羧酸，将其通过加热转化成5-取代的1-苯基-1 H-吡唑以优异的产率转化。的反应II与甲基肼在3-和一般的混合物，得到5-取代的乙基1-甲基-1- ħ-吡唑-4-羧酸酯，除IIg以外，产生高产率的5-苄基-1-甲基-1 H-吡唑-4-羧酸甲酯，将其水解为相对的吡唑羧酸。通过以定量收率加热5-苄基-1-甲基-1 H-吡唑来提供。

  DOI：

  10.1002/jhet.5570240634

文献信息

• Design, Synthesis, In Silico Docking Studies, and Antibacterial Activity of Some Thiadiazines and 1,2,4-Triazole-3-Thiones Bearing Pyrazole Moiety
  作者：Soukhyarani Gopal Nayak、Boja Poojary

  DOI：10.1134/s1068162020010069

  日期：2020.1

  analyses, mass spectrometry, FT-IR, 1 H, and 13 CNMR spectroscopy. To study the binding interactions of the derivatives with the receptor, they were docked with the prostaglandin D2 synthase (PGDS). The docking pose and non-covalent interactions gave insights into their plausible inhibitory action. They showed good antibacterial activity against Staphylococcus aureus , Enterococcus faecalis , Escherichia

  摘要 为了开发新的生物活性化合物，一系列 6-(取代-苯基)-3-(5-甲基-1-苯基-1 H-吡唑-4-基)-7 H-[1,2,4 ]三唑并[3,4-b][1,3,4]噻二嗪和4-[(取代-亚苄基)氨基]-5-(5-甲基-1-苯基-1H-吡唑-4-基)- 2,4-二氢-3 H -1,2,4-三唑-3-硫酮以良好的收率合成。这些化合物通过元素分析、质谱、FT-IR、 1 H 和 13 CNMR 光谱证实。为了研究衍生物与受体的结合相互作用，将它们与前列腺素 D2 合酶 (PGDS) 对接。对接姿势和非共价相互作用提供了对它们可能的抑制作用的见解。它们对金黄色葡萄球菌、粪肠球菌、大肠杆菌和铜绿假单胞菌显示出良好的抗菌活性。特别是氯、氟、二甲氧基、
• [EN] NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME<br/>[FR] NOUVEAUX COMPOSES AGONISTES DE PPAR DOLLAR G(G) ET PPAR DOLLAR G(A), LEUR METHODE DE PREPARATION ET COMPOSITION PHARMACEUTIQUE LES CONTENANT
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2005040127A1

  公开（公告）日：2005-05-06

  The present invention relates to novel compounds accelerating the activity of Peroxisome proliferator-activated receptor gamma (PPARϜ) and alpha (PPARα), processes of preparing the same, and pharmaceutical compositions containing the same as an active agent.

  本发明涉及一种新型化合物，可加速过氧化物酶体增殖物激活受体γ（PPARϜ）和α（PPARα）的活性，以及制备这种化合物的方法，以及含有该化合物作为活性成分的药物组合物。
• Microwave-Assisted Solution-Phase Synthesis of 1,4,5-Trisubstituted Pyrazoles
  作者：Giampaolo Giacomelli、Andrea Porcheddu、Margherita Salaris、Maurizio Taddei

  DOI：10.1002/ejoc.200390091

  日期：2003.2

  A small parallel library of 1,4,5-trisubstituted pyrazoles was prepared in solution using a three-step procedure starting from Meldrum acid. The Meldrum acid was acylated with different acyl chlorides and the products opened with different alcohols and amines to give substituted β-keto esters and β-keto amines. Further reaction with N,N-dimethylformamide dimethylacetal and the final cyclisation were

  使用三步法从 Meldrum 酸开始，在溶液中制备了一个小型的 1,4,5-三取代吡唑平行库。Meldrum酸用不同的酰氯酰化，产物用不同的醇和胺打开，得到取代的β-酮酯和β-酮胺。与 N,N-二甲基甲酰胺二甲基缩醛的进一步反应和最终的环化在微波辐射下有效地进行。在第一步中仅使用清除剂树脂，而在其他两个步骤中使用微波可以使起始材料完全转化。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003)
• Ramoplanin derivatives possessing antibacterial activity
  申请人：Raju G. Bore

  公开号：US20060211603A1

  公开（公告）日：2006-09-21

  Novel ramoplanin derivatives are disclosed. These ramoplanin derivatives exhibit antibacterial activity. As the compounds of the subject invention exhibit potent activities against gram positive bacteria, they are useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.

  新型拉莫普兰衍生物已被披露。这些拉莫普兰衍生物表现出抗菌活性。由于本发明的化合物对革兰氏阳性细菌表现出强效活性，它们是有用的抗微生物药剂。该化合物的合成方法和使用方法也已被披露。
• Design, synthesis, and pharmacological studies of some new Mannich bases and S-alkylated analogs of pyrazole integrated 1,3,4-oxadiazole
  作者：Shivapura Viveka、Dinesha、Prasanna Shama、Gundibasappa Karikannar Nagaraja、Nagaraju Deepa、Marikunte Yanjarappa Sreenivasa

  DOI：10.1007/s11164-015-2170-7

  日期：2016.3

  A facile and convenient synthesis of Mannich bases 5a – f and S -alkylated derivatives 6a – f and 7a – f has been carried out from the key intermediate 5-(5-methyl-1-phenyl-1 H -pyrazol-4-yl)-1,3,4-oxadiazole-2(3 H )-thione ( 4 ). Intermediate 4 was obtained from one-pot reaction of ethyl acetoacetate, phenylhydrazine, and N , N -dimethylformamide dimethyl acetal (DMF-DMA) followed by reaction with

  从关键中间体5-（5-甲基-1-苯基-1 H- 吡唑-4-基）进行了 曼尼希碱 5a - f 和 S- 烷基化衍生物 6a - f 和 7a - f的 简便合成 ）-1,3,4-恶二唑-2（3 H ）-硫酮（ 4 ）。中间体 4 是从一锅乙酰乙酸乙酯，苯肼和 N ， N的 反应中获得的 -二甲基甲酰胺二甲基乙缩醛（DMF-DMA），然后与水合肼和二硫化碳反应。根据元素分析，红外（IR），1 H核磁共振（NMR），13 C NMR和质谱数据建立了新合成化合物的结构。筛选所有合成的化合物的体内抗炎，体内止痛和体外抗微生物活性。从活性研究中可以得出结论，在所有衍生物中，化合物 5c ， 5e ， 5f ， 6c ， 7b 和 7c 显示出有效的抗炎活性，而 5b ， 图5c ， 图5e ， 图5f ， 6C ， 6F ， 图7b ， 图7c 和 7e中 显示出良好的镇痛活性。化合物 6a ， 6c